ClinConnect ClinConnect Logo
Search / Trial NCT02101255

Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions

Launched by CREDENTIS AG · Mar 28, 2014

Trial Information

Current as of May 06, 2025

Completed

Keywords

Dental Caries Curodont Repair P11 4

ClinConnect Summary

All study participants must have two early approximal carious lesions in need of a treatment but not of an invasive treatment (split-mouth design). One lesion will be treated with Curodont Repair and one with fluoride as control. Study duration is 24 months. For assessment x-ray pictures, Diagnodent Pen and DiagnoCam is used.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Two approximal carious lesions on different teeth with at least one tooth in between
  • 2. Both study lesions must not require an invasive treatment
  • 3. Size and form of the lesions: the lesions must be fully visible and assessable on radiographs
  • 4. The two carious lesions must fall into classes:
  • D2 (inner half of enamel)
  • D3 (outer part of dentine) but only if very little dentine is involved (enamel-dentine junction)
  • 5. Able and willing to observe good oral hygiene throughout the study
  • 6. Age ≥ 18 years and ≤ 65 years
  • 7. Willing and able to attend the on-study visits
  • 8. Willing and able to understand all study-related procedures
  • 9. Written informed consent before participation in the study
  • Exclusion Criteria:
  • 1. The two study test lesions are located on adjacent teeth
  • 2. Fluoride varnish application \< 3 months prior to study treatment
  • 3. Tooth with numerous carious lesions
  • 4. Evidence of tooth erosion
  • 5. History of head and neck illnesses (e.g. head/neck cancer)
  • 6. Any pathology or concomitant medication affecting salivary flow or dry mouth
  • 7. Any metabolic disorders affecting bone turnover
  • 8. Patient suffers from diabetes
  • 9. Concurrent participation in another clinical trial
  • 10. Women who are breast-feeding, pregnant or who plan a pregnancy during the study
  • 11. Women of childbearing potential who declare being unwilling or unable to practice contraception such as hormonal contraceptives, sexual abstinence or intercourse with a vasectomised partner

About Credentis Ag

Credentis AG is a leading Swiss biotechnology company specializing in the development of innovative dental therapies and products. Focused on enhancing oral health, Credentis leverages cutting-edge technologies to create solutions that address unmet needs in dental care, including minimally invasive treatments and regenerative approaches. With a commitment to research and development, the company aims to improve patient outcomes and quality of life through its clinically validated products, demonstrating a strong dedication to advancing the field of dentistry.

Locations

Sirnach, Thurgau, Switzerland

Patients applied

0 patients applied

Trial Officials

Mathias Seifert, Med. dent.

Principal Investigator

Zahnheilkunde Seifert Gmbh

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials